US Malabsorption Syndrome Market Summary

As per Market Research Future analysis, the US malabsorption syndrome market size was estimated at 639.31 USD Million in 2024. The US malabsorption syndrome market is projected to grow from 675.43 USD Million in 2025 to 1170.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US malabsorption syndrome market is experiencing notable growth driven by increased awareness and innovative treatment options.

Rising awareness and diagnosis of malabsorption syndrome are leading to earlier interventions and improved patient outcomes.
Innovative dietary solutions are emerging as a key focus area, catering to the specific nutritional needs of affected individuals.
Advancements in treatment options, including new pharmaceuticals and therapies, are enhancing the management of malabsorption syndrome.
The increasing prevalence of gastrointestinal disorders and growing demand for nutritional supplements are significant drivers of market expansion.

Market Size & Forecast

2024 Market Size	639.31 (USD Million)
2035 Market Size	1170.0 (USD Million)
CAGR (2025 - 2035)	5.65%

Major Players

AbbVie (US), Takeda Pharmaceutical Company Limited (JP), Nestle Health Science (CH), Johnson & Johnson (US), Boehringer Ingelheim (DE), Mylan N.V. (US), Purdue Pharma L.P. (US), Ferring Pharmaceuticals (CH)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

US Malabsorption Syndrome Market Trends

This market is characterized by a growing awareness of gastrointestinal disorders and their impact on overall health. This condition, which affects the body's ability to absorb nutrients from food, has garnered increased attention from healthcare professionals and patients alike. As a result, there is a rising demand for diagnostic tools and treatment options tailored to address the specific needs of individuals suffering from malabsorption syndromes. The market appears to be evolving, with advancements in medical technology and a focus on personalized medicine potentially enhancing patient outcomes. Moreover, the malabsorption syndrome market is influenced by various factors, including dietary trends and lifestyle changes. The increasing prevalence of conditions such as celiac disease and lactose intolerance has led to a surge in the development of specialized dietary products. These products aim to cater to the unique nutritional requirements of affected individuals, thereby expanding the market landscape. Additionally, ongoing research into the underlying causes of malabsorption syndromes may lead to innovative therapies and improved management strategies, further shaping the future of this market.

Rising Awareness and Diagnosis

There is a notable increase in awareness regarding malabsorption syndromes among healthcare providers and patients. This heightened awareness is likely leading to more accurate diagnoses and earlier interventions, which could improve patient outcomes. As a result, the demand for diagnostic tests and related services is expected to grow.

Innovative Dietary Solutions

The malabsorption syndrome market is witnessing a trend towards the development of innovative dietary solutions. Companies are focusing on creating specialized food products that cater to the nutritional needs of individuals with malabsorption issues. This trend may enhance the quality of life for patients and expand market opportunities.

Advancements in Treatment Options

Ongoing research and development in the field of gastrointestinal health are paving the way for new treatment options for malabsorption syndromes. These advancements may include novel medications and therapies that target the underlying causes of malabsorption, potentially transforming the management of these conditions.

US Malabsorption Syndrome Market Drivers

Rising Healthcare Expenditure

The increasing healthcare expenditure in the US is a significant driver for the malabsorption syndrome market. As healthcare budgets expand, there is a greater focus on improving patient care and access to specialized treatments. This trend is evident in the growing investment in research and development for new therapies and diagnostic tools aimed at addressing malabsorption syndromes. In 2025, healthcare spending in the US is projected to exceed $4 trillion, which could lead to enhanced funding for malabsorption-related research. This influx of resources is likely to stimulate innovation and improve treatment options, thereby positively impacting the malabsorption syndrome market.

Advancements in Diagnostic Technologies

Technological innovations in diagnostic tools are transforming the malabsorption syndrome market. Enhanced imaging techniques, such as MRI and CT scans, along with advanced laboratory tests, are facilitating earlier and more accurate diagnoses. These advancements not only improve patient outcomes but also drive market growth by increasing the number of diagnosed cases. The introduction of non-invasive testing methods is particularly noteworthy, as they reduce the need for invasive procedures, making diagnosis more accessible. As a result, This market is expected to expand, with a compound annual growth rate (CAGR) of approximately 8% over the next five years, reflecting the impact of these technological advancements.

Growing Demand for Nutritional Supplements

The increasing awareness of nutritional deficiencies associated with malabsorption syndromes is driving the demand for dietary supplements in the malabsorption syndrome market. Patients often require specialized nutritional support to manage their conditions effectively. The market for nutritional supplements is projected to reach $500 million by 2026, as more individuals seek products that can help mitigate the effects of malabsorption. This trend is further fueled by the rise of health-conscious consumers who are more inclined to invest in their well-being. Consequently, manufacturers are focusing on developing innovative supplements tailored to the needs of those with malabsorption issues, thereby enhancing the overall market landscape.

Enhanced Patient Education and Support Programs

The establishment of patient education and support programs is playing a pivotal role in the malabsorption syndrome market. These initiatives aim to inform patients about their conditions, treatment options, and dietary management strategies. Increased patient knowledge can lead to earlier diagnosis and better adherence to treatment regimens, ultimately improving health outcomes. Organizations and healthcare providers are increasingly investing in these programs, recognizing their potential to empower patients. As a result, the malabsorption syndrome market is likely to benefit from a more informed patient population, which may drive demand for diagnostic and therapeutic solutions.

Increasing Prevalence of Gastrointestinal Disorders

The rising incidence of gastrointestinal disorders in the US is a crucial driver for the malabsorption syndrome market. Conditions such as celiac disease, Crohn's disease, and irritable bowel syndrome are becoming more prevalent, leading to a higher demand for diagnostic and therapeutic solutions. According to recent estimates, approximately 1 in 100 individuals in the US are affected by celiac disease alone. This growing patient population necessitates increased awareness and improved treatment options, thereby propelling the malabsorption syndrome market forward. As healthcare providers become more vigilant in diagnosing these conditions, the market is likely to experience significant growth, with a projected increase in market value reaching $1.5 billion by 2027.

Market Segment Insights

By causative diseases: Celiac disease (Largest) vs. Lactose intolerance (Fastest-Growing)

The US malabsorption syndrome market is characterized by diverse causative diseases, with Celiac disease holding the largest market share due to its high prevalence and awareness. Other significant contributors include Cystic fibrosis, Parasitic diseases, and Intestinal disorders, which collectively present a notable portion of the market. Emerging diseases such as Lactose intolerance and Whipple’s disease are gaining traction, indicating potential shifts in market dynamics. Growth trends in the US malabsorption syndrome market are driven by increasing awareness of symptoms and diagnosis of previously underreported conditions. Lactose intolerance is emerging as the fastest-growing segment as healthcare providers better recognize its prevalence. Additionally, advancements in diagnostic technologies and treatment options are expected to enhance patient outcomes, further fueling market growth and improving access to necessary healthcare services.

Celiac disease (Dominant) vs. Lactose intolerance (Emerging)

Celiac disease remains the dominant segment within the US malabsorption syndrome market, largely attributed to heightened awareness and robust diagnostic measures that support its identification. Patients diagnosed with Celiac disease often require strict adherence to gluten-free diets, which significantly impacts their quality of life and dietary choices. In contrast, lactose intolerance represents an emerging segment, characterized by growing recognition and understanding among the general population. This segment is increasingly being addressed by food manufacturers, who are introducing lactose-free products to cater to those affected, thereby enhancing market accessibility and driving growth. The agility of the lactose intolerance segment in adapting to consumer needs demonstrates its potential to reshape the market landscape in the coming years.

By diagnosis: Imaging studies (Largest) vs. Hematologic tests (Fastest-Growing)

In the US malabsorption syndrome market, the segment distribution shows that imaging studies hold a significant share, driven by the increasing demand for non-invasive diagnostic techniques. Among various modalities, CT scans and abdominal x-rays are particularly popular due to their effectiveness in identifying structural anomalies. Conversely, hematologic tests, which include multiple blood tests designed to identify malabsorption, are gaining momentum, reflecting a shift towards more thorough yet efficient diagnostic methods. The growth trends within this segment are fueled by advancements in technology and a greater awareness of malabsorption conditions among healthcare providers. Hematologic tests are emerging as essential tools, featuring innovations that reduce turnaround time and improve diagnostic accuracy. Factors like the increasing incidence of digestive disorders and rising healthcare expenditure contribute to the expanding role of diagnostic tests in managing malabsorption, making these segment values critical for future market dynamics.

Imaging studies (Dominant) vs. Hematologic tests (Emerging)

The imaging studies segment stands out as the dominant force in the market, characterized by its array of techniques such as CT scans and abdominal x-rays, which provide clear, detailed visualizations crucial for diagnosing malabsorption. These methods are favored for their speed and accuracy, making them the go-to choice for initial assessments. On the other hand, hematologic tests, emerging as vital contributors, are witnessing rapid adoption due to their capability to assess absorption issues through blood analysis. These tests can pinpoint specific deficiencies and drive personalized treatment plans. The combination of imaging studies and hematologic tests reflects a comprehensive approach to diagnosis, with each serving distinct yet complementary roles in the overall management of malabsorption syndromes.

By treatment: Gluten-free diet (Largest) vs. Nutritional supplements (Fastest-Growing)

In the US malabsorption syndrome market, the treatment segment is increasingly diverse, with various approaches gaining traction among consumers. Currently, the gluten-free diet stands out as the largest segment, reflecting significant adherence among those suffering from gluten-related disorders. In contrast, nutritional supplements have emerged as a fast-growing segment, capturing the attention of patients seeking alternative therapies. The growth trends within this segment are driven by rising awareness of malabsorption syndromes and a shift towards holistic health approaches. Patients are increasingly inclined to explore diverse treatment options, such as anti-inflammatory drugs and protease and lipase supplements, that provide targeted relief. The expansion of online health resources and support communities further fuels demand for these treatments, facilitating informed choices and fostering market growth.

Gluten-free diet (Dominant) vs. Nutritional supplements (Emerging)

The gluten-free diet has become the dominant treatment option in the US malabsorption syndrome market, primarily due to its effectiveness in managing symptoms related to gluten intolerance. Many individuals find significant relief through strict adherence to this dietary regimen. On the other hand, nutritional supplements are gaining traction as an emerging solution, especially among patients looking for additional ways to support their health. These supplements are often rich in vitamins and minerals that patients with malabsorption may lack. The rise in popularity of personalized nutrition has also contributed to the development of specialized supplements tailored for specific deficiencies. Overall, both segments play crucial roles in enhancing patient outcomes and meeting the diverse needs of those affected by malabsorption syndromes.

By end-user: Hospitals (Largest) vs. Nutrition Clinics (Fastest-Growing)

In the US malabsorption syndrome market, the distribution of market share among the end-user segments is notably polarized. Hospitals currently command the largest share, attributed to their extensive patient base and advanced diagnostic capabilities. In contrast, nutrition clinics are emerging as a significant segment, driven by increased awareness around dietary management of malabsorption issues and personalized nutrition services, indicating a diversification in healthcare approaches. Growth trends in this segment reflect a broader shift toward specialized care and outpatient services. The expansion of nutrition clinics is fueled by the rising prevalence of malabsorption conditions and a growing emphasis on preventative health strategies. Hospitals continue to invest in advanced treatments and technology, while academic research and partnerships are enhancing the development of effective management solutions, indicating a robust ecosystem fostering innovation.

Hospitals (Dominant) vs. Nutrition Clinics (Emerging)

Hospitals play a dominant role in the US malabsorption syndrome market due to their established infrastructure, comprehensive patient care facilities, and access to advanced diagnostic tools. They are equipped to handle complex cases and offer a wide range of treatments, contributing significantly to their market share. Conversely, nutrition clinics are emerging rapidly, driven by a proactive approach to managing malabsorption through dietary interventions and nutritional counseling. These clinics focus on tailored therapies that reflect individual patient needs, representing a shift towards personalized medical care. As they expand their services and increase awareness of malabsorption issues, nutrition clinics are gaining traction, positioning themselves as crucial players in this evolving market landscape.

Get more detailed insights about US Malabsorption Syndrome Market

Request Free Sample

Key Players and Competitive Insights

The malabsorption syndrome market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie (US), Takeda Pharmaceutical Company Limited (JP), and Nestle Health Science (CH) are actively engaged in enhancing their product offerings and expanding their market presence. AbbVie (US) has positioned itself as a leader in the development of biologics and specialty pharmaceuticals, focusing on innovative therapies that address the underlying causes of malabsorption syndromes. Meanwhile, Takeda Pharmaceutical Company Limited (JP) emphasizes its commitment to research and development, particularly in gastrointestinal disorders, which aligns with the growing demand for targeted treatments. Nestle Health Science (CH) leverages its expertise in nutritional science to provide specialized nutritional products that support patients with malabsorption issues, thereby enhancing its competitive edge. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The malabsorption syndrome market appears moderately fragmented, with a mix of established players and emerging companies vying for market share. The collective influence of these key players is significant, as they not only drive innovation but also set industry standards that smaller firms must adhere to in order to remain competitive. In October 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel therapeutic agent aimed at treating specific malabsorption syndromes. This collaboration is expected to enhance AbbVie's research capabilities and accelerate the development timeline for new treatments, thereby reinforcing its position in the market. The strategic importance of this partnership lies in its potential to bring innovative solutions to patients more rapidly, addressing unmet medical needs in the malabsorption space. In September 2025, Takeda Pharmaceutical Company Limited (JP) launched a new clinical trial for a groundbreaking therapy targeting patients with celiac disease, a common malabsorption syndrome. This initiative underscores Takeda's commitment to advancing treatment options and highlights its focus on evidence-based medicine. The trial's outcomes could significantly influence treatment protocols and establish Takeda as a frontrunner in the field. In August 2025, Nestle Health Science (CH) expanded its product line with the introduction of a new range of nutritional supplements specifically designed for individuals with malabsorption disorders. This move not only diversifies Nestle's offerings but also aligns with the growing trend towards personalized nutrition. The strategic importance of this expansion is evident in its potential to capture a larger market share by addressing the specific dietary needs of patients, thereby enhancing overall health outcomes. As of November 2025, the competitive trends in the malabsorption syndrome market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in product development and patient care. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient outcomes. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in an increasingly complex and dynamic market.

Key Companies in the US Malabsorption Syndrome Market include

Future Outlook

US Malabsorption Syndrome Market Future Outlook

The Malabsorption Syndrome Market is projected to grow at a 5.65% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in diagnostic technologies.

New opportunities lie in:

Development of personalized nutrition plans for patients
Expansion of telehealth services for remote patient monitoring
Investment in innovative drug delivery systems for enhanced treatment efficacy

By 2035, the malabsorption syndrome market is expected to achieve substantial growth and innovation.

Market Segmentation

US Malabsorption Syndrome Market end-user Outlook

Hospitals
Academic and Research Institutes
Pharmaceutical companies
Nutrition Clinics
Others

US Malabsorption Syndrome Market diagnosis Outlook

Imaging studies
CT scan
Endoscopic retrograde cholangiopancreatogram (ERCP)
Magnetic resonance cholangiopancreatography (MRCP)
Abdominal x-ray
Hematologic tests
Other tests
Test of fat malabsorption
Tests of carbohydrate absorption
Schilling test
D-xylose test
Test of bile salt absorption
C-d-xylose breath test

US Malabsorption Syndrome Market treatment Outlook

Gluten-free diet
Anti-inflammatory drugs
Antibiotics
Nutritional supplements
Protease and lipase supplements
Antidiarrheal agents
Others

US Malabsorption Syndrome Market causative diseases Outlook

Cystic fibrosis
Parasitic diseases
Intestinal disorders
Celiac disease
Others
Lactose intolerance
Whipple’s disease
Tropical sprue
Others

Report Scope

MARKET SIZE 2024	639.31(USD Million)
MARKET SIZE 2025	675.43(USD Million)
MARKET SIZE 2035	1170.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.65% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	AbbVie (US), Takeda Pharmaceutical Company Limited (JP), Nestle Health Science (CH), Johnson & Johnson (US), Boehringer Ingelheim (DE), Mylan N.V. (US), Purdue Pharma L.P. (US), Ferring Pharmaceuticals (CH)
Segments Covered	causative diseases, diagnosis, treatment, end-user
Key Market Opportunities	Advancements in diagnostic technologies enhance early detection and treatment options in the malabsorption syndrome market.
Key Market Dynamics	Rising demand for innovative therapies drives competition and regulatory scrutiny in the malabsorption syndrome market.
Countries Covered	US

FAQs

What is the current valuation of the US malabsorption syndrome market?

The market valuation was $639.31 Million in 2024.

What is the projected market size for the US malabsorption syndrome market by 2035?

The projected valuation for 2035 is $1,170.0 Million.

What is the expected CAGR for the US malabsorption syndrome market during the forecast period?

The expected CAGR for the market from 2025 - 2035 is 5.65%.

Which companies are the key players in the US malabsorption syndrome market?

Key players include AbbVie, Takeda Pharmaceutical Company Limited, Nestle Health Science, Johnson & Johnson, Boehringer Ingelheim, Mylan N.V., Purdue Pharma L.P., and Ferring Pharmaceuticals.

What are the major segments of the US malabsorption syndrome market by causative diseases?

Major segments include Celiac disease, Intestinal disorders, Lactose intolerance, and Cystic fibrosis, with valuations ranging from $20.0 Million to $350.0 Million.

How is the US malabsorption syndrome market segmented by diagnosis?

The market is segmented by diagnosis into imaging studies, CT scans, and hematologic tests, with valuations from $5.0 Million to $90.0 Million.

What treatment options are available in the US malabsorption syndrome market?

Treatment options include gluten-free diets, anti-inflammatory drugs, and nutritional supplements, with valuations between $35.45 Million and $227.0 Million.

What are the end-user segments in the US malabsorption syndrome market?

End-user segments include hospitals, academic and research institutes, and nutrition clinics, with valuations from $63.93 Million to $460.0 Million.

How does the market performance of Celiac disease compare to other segments?

Celiac disease leads the market with a valuation range of $200.0 Million to $350.0 Million, surpassing other segments.

What trends are expected in the US malabsorption syndrome market by 2035?

The market is likely to experience growth driven by increasing awareness and advancements in treatment options, reaching $1,170.0 Million by 2035.

Author

Author

Satyendra Maurya

Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment